specialty focus
a list of oncogenes and asked questions
about the ages of the genes and their
function after they cluster around certain
properties. What she found was that a
set of these oncogenes are just like – the
technical term is homologues – the genes
you find in bacteria that can turn up the
mutation rates of bacteria when they’re
under stress.
There’s a well-known phenomenon that
if you starve bacteria – so if they normally
feed on glucose and you deprive them
of glucose – they can metabolise other
sugars, and they will turn up their rates of
mutation to find one that will enable them
to metabolise other sources of food. It’s
often called an SOS response, and it’s been
much studied.
So the mutation rate is actually not just
God given, it’s partially under the control
of organisms. They can tune their own
mutation rates and, lo and behold, a
subset of cancer genes has that property
of being just like the genes in bacteria of
turning up the mutation rate. Now, one of
the hallmarks of cancer is its rapid rate of
mutation. That’s what makes it so hard to
treat with chemotherapy because it just
evolves resistance to any particular drug.
So the discovery that this is a sort of self-
inflicted process, that the mode of mutation
is the same when you look at the pattern
of mutation in cancer cells and the pattern
of mutation in bacterial cells in quite some
detail, they really do match up. This is a very
ancient stress response.
So the therapeutic aspects of this are
pretty obvious. The more stressed a cell
feels, the more likely it is to invoke this SOS
response. And so the standard of practice
in cancer treatment – in many cases, not all
– tends to be maximum tolerable dose: you
flood the patient with a toxin in the hope
that the cancer dies before the patient dies.
We think we should get away from that,
but that’s likely to be counterproductive
because the elevation of stress on the
cancer cell is much more likely to trigger
this SOS response. What we would like
to see is cancer that, instead of trying to
annihilate it, we try to live with it. That is,
use therapeutic agents, but use them in
the lowest doses that can hold the cancer
in check.
This is rather a psychological issue.
Many people react badly to cancer. They
feel, “I’ve got cancer. I want every cancer
cell in my body eradicated.” Well, that is
simply impossible.
We need to get used to the idea that
cancer is a normal part of ageing, that you
have cancers in you and most of them are
managed okay, and if one of them breaks
out and the body’s not coping with it, we
help the body to maintain it and treat it as
a chronic disease, not something that we
must eradicate with toxins and so on.
One of the ideas suggested in your piece
was potentially treating cancer with the
introduction of viruses.
Yes. About 100 years ago, an American
physician, William Coley, noticed that some
cancers would spontaneously vanish if
the patient got an infectious disease. This
was more common before the era of
sterilisation. So Coley started deliberately
infecting his cancer patients with a
particular disease.
The great hope in cancer treatment at
the moment seems to be immunotherapy,
where you’d try to boost the body’s own
immune system to take care of the cancer.
The standard explanation for Coley’s
results is that the infection boosted the
immune system and the cancer was
knocked off as collateral damage. We
think that at least part of the story is that
the cancer tumours themselves are more
susceptible to infection than the healthy
tissues. And part of the reason for that
is one of the hallmarks of cancer is it
decouples from the body’s immune system.
It can screen the immune system out. That’s
one of the ways it gets around the immune
system trying to attack it.
So we think that tumours are actually
more vulnerable to infections than the
healthy part of the body. This is another way
to interpret Coley’s experiments. We should
think seriously about injecting tumour tissue
and with a variety of – it doesn’t have to be
bacteria, it can be viruses, or even a fungal
agent. The point being that tumours are
more vulnerable to disease, so that gives
another therapeutic line of attack that I think
is worth investigating. And a few people
do seem to be producing results around
those ideas. But this is very much in its
early stages.
What are the possible implications from
your theories for the health system and
our approach to cancer?
It’s unrealistic to expect there to be a cure. I
call this the ‘lure of the cure’ – the idea that
there’s a pill that will make it go away. Some
sort of general-purpose cancer pill I think is
a complete waste of time and money. We’re
not going to ever achieve that. There have
been some success stories with individual
cancers, and it would be wrong to belittle
that. Childhood leukaemia, for example,
is largely conquered, if we’re going to use
that sort of military expression. But I think
in the vast majority of cancers, we have to
get to this point of view that they should be
managed rather than eradicated. I’m a fan of
looking for ways of stabilising cancer other
than using chemical toxins.
One idea I’ve been interested in – though
there haven’t been any real clinical trials – is
hyperbaric oxygen therapy.
The point here is that a cancer, in its
reversion to this more primitive phenotype,
switches to a different form of metabolism.
Healthy cells use a process called oxidative
phosphorylation to get their energy. Cancer
cells use a different mechanism, called
glycolysis. It takes sugar and it’s not very
energy efficient, but it’s good at making
biomass. So, if the name of the game is
more bulk, which is what humans do, but
they need less energy, then this glycolysis
is a good way to go. It’s often called
fermentation as well because it’s the same
process. In a nutshell, healthy cells like lots
of oxygen; cancer cells can work in very low
levels of oxygen, a bit like it was on Earth
two billion years ago. So, they like lots of
sugar and not much oxygen.
So the plan is you hold them in check.
You turn this around the other way: you
turn off the sugar, through diet, and
turn up the oxygen through hyperbaric
oxygen therapy, which is available for use
for many conditions. This is something
which is already familiar in various medical
treatments: you put the patient into a
chamber at two atmospheres, pure oxygen,
for half an hour or something. So we think
combined with something like a ketogenic
diet, hyperbaric oxygen therapy could
stabilise tumours, and that’s all you need
to do. I should emphasise, again, that you
don’t have to eradicate them, so long as
tumours don’t spread, or if they do spread,
they don’t cause problems in the secondary
side. So long as it’s stable, what more could
you want?
It’s very hard, though, with the way the
medical system works, to get much traction
behind something that doesn’t involve a
new chemical agent or something that a
drug company can make. Oxygen is pretty
much free; you can change your diet for
nothing, and what I’m advocating here is
not anything that’s likely to make money.
So, under those circumstances, it’s hard
to get anyone to pay for a clinical trial,
because the only reason people do clinical
trials is if there’s likely to be a large profit at
the end of it – a sad state of affairs. ■
nursingreview.com.au | 19